Beam Therapeutics Inc. (BEAM)

Market Cap	2.17B -10.8%
Revenue (ttm)	139.74M +120.0%
Net Income	-79.99M
EPS	-0.81
Shares Out	99.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,247,740
Open	22.30
Previous Close	22.19
Day's Range	21.63 - 22.77
52-Week Range	13.53 - 36.44
Beta	2.17
Analysts	Strong Buy
Price Target	52.21 (+138.4%)
Earnings Date	May 5, 2026

About BEAM

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 6, 2020
• Employees: 511
• Stock Exchange: NASDAQ
• Ticker Symbol: BEAM
• Website: https://beamtx.com

Financial Performance

In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.

Analyst Summary

According to 14 analysts, the average rating for BEAM stock is "Strong Buy." The 12-month stock price target is $52.21, which is an increase of 138.40% from the latest price.

Price Target

$52.21

(138.40% upside)

Analyst Consensus: Strong Buy